LPL Financial
PLX icon

LPL Financial’s Protalix BioTherapeutics PLX Stock Holding History

LPL Financial’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.3K Hold
10,291
– – ﹤0.01% 5868
2025
Q4 		$18.5K Hold
10,291
– – ﹤0.01% 5812
2025
Q3 		$22.8K Buy
+10,291
New +$16.8K ﹤0.01% 5732

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

LPL Financial's PLX Position: Q1 2026 in Review

LPL Financial held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 10,291 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5868.

LPL Financial first reported a position in PLX in Q3 2025 and has held it in 3 quarters since. The position peaked at $22.8K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • LPL Financial held 10,291 shares of Protalix BioTherapeutics worth $22.3K as of Q1 2026.
  • LPL Financial left its Protalix BioTherapeutics share count unchanged in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5868 holding.
  • LPL Financial first reported a position in Protalix BioTherapeutics in Q3 2025 and has held it in 3 quarters since.
  • LPL Financial's Protalix BioTherapeutics position peaked at $22.8K in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.